TNFSF10 and head and neck squamous cell carcinoma: In this study, we tested the response of HPV+ and HPV− HNSCC cells to treatment with TRAIL alone or combined with bortezomib, revealing a clear pattern of sensitivity to TRAIL depending on HPV status and a synergistic effect when combined with bortezomib.